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Abstract
Background: The most common physical deficit caused by a stroke is muscle weakness which limits a person’s mobility.
Mobility encompasses activities necessary for daily functioning: getting in and out bed, on/off toilet, sitting, standing and
walking. These activities are significantly affected in people with severe stroke who typically spend most of their time in
bed or a chair and are immobile. Immobility is primarily caused by neurological damage but exacerbated by secondary
changes in musculoskeletal and cardiorespiratory systems. These secondary changes can theoretically be prevented or
minimised by early mobilisation, in this case standing up early post-stroke.
Standing up early post-stroke has been identified as an important priority for people who have suffered a severe stroke.
However, trials of prolonged passive standing have not demonstrated any functional improvements. Conversely, task-
specific training such as repeated sit-to-stand has demonstrated positive functional benefits. This feasibility trial combines
prolonged standing and task-specific strength training with the aim of determining whether this novel combination of
physiotherapy interventions is feasible for people with severe stroke as well as the overall feasibility of delivering the trial.
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Methods/design: This is a pragmatic multi-centre parallel single-blinded two-armed feasibility randomised controlled
trial. Fifty people with a diagnosis of severe stroke will be randomly allocated to either the functional standing frame
programme or usual physiotherapy. All patient participants will be assessed at baseline and followed up at 3 weeks, then
3, 6 and 12 months post-randomisation. Trial objectives are to determine the feasibility according to the following
indicators:: (i) Process: recruitment and retention rate, ability to consent, eligibility criteria, willingness/ability of
physiotherapists to recruit, willingness of patients to be randomised, and acceptability of the intervention; (ii) Resource:
burden and potential costs; (iii) Management: treatment fidelity, participant adherence, acceptability and completeness of
outcome measures, impact and management or orthostatic hypotension; and (iv) Safety: number and nature of adverse
and serious adverse events.
Discussion: The functional standing frame programme addresses a key concern for people who have suffered a severe
stroke. However, several uncertainties exist which need to be understood prior to progressing to a full-scale trial, including
acceptability and tolerance of the functional standing frame programme intervention and practicality of the trial
procedures. This feasibility trial will provide important insights to resolve these uncertainties.
Trial registration: International Standard Randomised Controlled Trial Number ISRCTN15412695. Registration on 19
December 2016.
Keywords: Stroke, Supported standing, Neuromuscular impairment, Physiotherapy, Function, Feasibility randomised
controlled trial, Early mobilisation
Background
Stroke is a sudden and devastating illness affecting over
100,000 people per annum in the United Kingdom (UK)
[53]. Current government and clinical guidelines recom-
mend that following diagnosis of a stroke, people are ad-
mitted to an Acute Stroke Unit to receive stroke
specialist multi-disciplinary care. This reduces mortality
and improves functional outcomes [40] compared to
standard non-specialist care. The UK stroke pathway
[44] and National Clinical Guidelines [34] advocate that
people with mild or moderate strokes (i.e. modified
Rankin Scale (mRS) 1–3; able to transfer independently
or with the help of one person with/without equipment)
are discharged from the Acute Stroke Unit to the Early
Supported Discharge service, which provides specialist
stroke rehabilitation in a home-based setting. People
with severe strokes (mRS 4–5; requiring assistance of
two people with/without equipment) are transferred
from the Acute Stroke Unit to a specialist Stroke
Rehabilitation Unit for early sub-acute rehabilitation
usually within 7 days. The early sub-acute phase spans
from 7 days to 3 months [6]), with average time from
stroke onset to admission on Stroke Rehabilitation Unit
6 days (1 to 37 days) [13]. Some Early Supported Dis-
charge services in the UK admit people with a mRS of 4,
but this is not the standard care nationally.
The implementation of Early Supported Discharge has
caused a change in patient caseload nationally for Stroke
Rehabilitation Units [54] resulting in the majority of people
admitted to Stroke Rehabilitation Units having complex
needs and severe deficits. This change in caseload necessi-
tates the design and evaluation of interventions for patients
in Stroke Rehabilitation Units that target people with more
severe deficits. The most common physical deficit caused
by stroke is motor impairment, seen in approximately 80%
of people [70]. It is the single most disabling factor in terms
of limiting a person’s mobility, their ability to participate in
activities of daily living (ADL) and to live independently
[67]. Mobility encompasses a wide range of activities neces-
sary for daily functioning: moving in bed, getting in/out of
bed, on/off toilet, sitting out of bed, standing and walking
[34]. These activities are particularly affected in the 15.5%
of people with severe stroke [54] who require the assistance
of two people to undertake ADL, may need equipment to
aid transfers and are unable to sit unsupported, stand or
walk [27]. They typically spend much of their time in bed
and are dependent on a wheelchair/specialist seating when
they sit out of bed [57].
Although immobility post-stroke is primarily caused by
neurological damage, it can be exacerbated by other factors
such as muscle wasting [56], reduced muscle length, in-
creased muscle stiffness [47], joint contracture [26] and
orthostatic hypotension. Orthostatic Hypotension (OH) is a
sudden drop in blood pressure when moving from lying to
standing, leading to symptoms of feeling faint, generalised
weakness, cognitive slowing, and gradual or sudden loss of
consciousness [38] and can, therefore, limit standing time. It
can affect over 50% of people post-stroke [37] and should be
addressed using non-pharmacological or pharmacological in-
terventions, or a combination of the two [49, 64]. Secondary
changes in the musculoskeletal and cardiorespiratory systems
can theoretically be prevented or minimised by early mobil-
isation [65] especially standing [46]; prevention of these sec-
ondary changes underpins the rationale for the current trial.
Logan et al. Pilot and Feasibility Studies  (2018) 4:66 Page 2 of 18
Several randomised controlled trials (RCTs) have
reported mixed outcomes of early mobilisation post-
stroke. Less favourable outcomes occurred when
early mobilisation was instigated very early (within
the first 24 h post-stroke) [62] compared to a reduc-
tion in complications when instigated early (≥ 24 h
post-stroke) [17]. Early mobilisation is associated
with increased independence in ADL and a faster re-
turn to walking [15]. However, these trials all had
different primary end-points (Functional Independ-
ence Measure; Modified Rankin; incidence of severe
complications during hospitalisation) which makes
direct comparison of effectiveness of early mobilisa-
tion interventions difficult. Whilst early mobilisation
is deemed to be safe [5, 15, 17, 62], uncertainties
have been identified with regard to dose and fre-
quency. The AVERT Trial Collaborative Group sug-
gest that shorter, more frequent mobilisation is
preferable, and the latest Royal College of Physicians
Guidelines have incorporated this, recommending
patients “accumulate” at least 45 min daily. However,
the main limitation of these studies is that they
specify neither the time spent mobilising nor the in-
tensity, content and frequency of therapy. Therefore,
it is possible in previous work that, other than
hoists, no specialised equipment was used to pro-
mote recovery for people with severe stroke, and
active sitting constituted early mobilisation with no
opportunity to stand. This is aligned with current
clinical practice in Cornwall and Devon (where this
research is being led) where standing is not routinely
implemented as part of sub-acute inpatient rehabili-
tation for people who have suffered a severe stroke.
A motorised standing frame can safely assist people with
severe stroke into a supported standing posture. Suggested
benefits of supported standing include stretching
contracted muscles, decreasing spasticity, strengthening
muscles, improving bladder and bowel function, relieving
pressure areas and reducing OH [2, 19, 31, 35, 45, 69].
Evidence from people with spinal cord injury, multiple
sclerosis, stroke and traumatic brain injury [2, 46, 60] indi-
cates that the aforementioned benefits can be observed
with 30 min of regular standing. However, a systematic re-
view highlighted variation in duration (20 to 60 min) and
frequency from three times per week (median 5 days per
week), with dose dependent on length of inpatient say and
participant recovery [46].
In preparation for this feasibility trial, discussions
with people who had suffered a stroke and their rel-
atives identified that standing up early after a stroke
was important, relevant and meaningful for them
and this formed the basis of the research question
and subsequent trial design/development. Opportunities
to stand for people who have suffered a severe stroke are
limited due to significant disability; thus, they are reliant
on physical assistance from mechanical equipment such
as a standing frame.
Standing frames are not routinely used in sub-acute
inpatient stroke rehabilitation as part of a postural man-
agement programme and never issued on discharge from
Stroke Rehabilitation Units. A systematic review [46]
identified a paucity of robust evidence for the use of
standing frames in people with stroke. A previous RCT
found no difference in functional outcomes in people
with a sub-acute severe stroke who did or did not use
standing frames for 14 consecutive sessions [1]. The lack
of functional improvement may be due to the duration
and intensity of treatment, as well as the sensitivity of
the outcome measures used (Rivermead Mobility Index
and Barthel Index). Additionally, participants undertook
prolonged passive standing only and the addition of
task-specific training may have improved functional out-
comes. Task-specific training is based on the fundamen-
tal principle that repeated practice of functionally
relevant tasks is the best way to learn [3, 23]. Tasks such
as sit-to-stand have been shown to produce functional
benefits post-stroke, and patients who receive task-
specific training are more likely to improve their
function and sustain these improvements than patients
receiving usual care [23, 63]. The combination of
prolonged standing and task-specific strength training
underpins the rationale for the functional standing frame
programme used in this feasibility trial.
The functional standing frame intervention com-
bines two physiotherapy interventions that have sep-
arately been evaluated and reported in the literature:
prolonged standing and task-specific strength train-
ing. Currently, it is not known whether this novel
combination of physiotherapy for people with severe
stroke is effective in everyday clinical practice, and
the United Kingdom Medical Research Council pro-
vides guidance on how complex interventions can be
developed and evaluated [42]. A key component of
the evaluation of the complex intervention is the
acceptability among people with severe stroke.
Currently, it is not known whether the functional
standing frame programme would be tolerated or ac-
ceptable for people with severe stroke, at this early
stage of their rehabilitation continuum. The Medical
Research Council guidance explicitly recommends an
early phase of assessing feasibility prior to a full
definitive main trial [43] and recognises the value of
using both quantitative and qualitative methods con-
currently. The use of qualitative research within
feasibility RCTs is becoming increasingly common
[48]. This feasibility randomised controlled trial
facilitates the evaluation of acceptability, compliance
and delivery of the intervention; trial practices,
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processes and design; and recruitment and refusal
and retention rates. This links to the trial objectives and
will inform the conduct and design of the anticipated de-
finitive main trial to facilitate successful, effective and
confident delivery.
Qualitative research will be embedded in this feasibil-
ity trial and used in tandem with quantitative methods
to provide insights into the intervention and trial
processes.
Aims
The primary aim of this trial is to establish whether a RCT
of a functional standing frame programme in people with
severe stroke in an inpatient sub-acute stroke rehabilitation
setting is feasible.
The secondary aim is to explore the experience of this
functional standing frame programme on the individual’s
daily life, as well as the experience of being recruited
and randomised to the trial, from the perspective of both
the person with stroke and their relative/carer, using
qualitative methods.
Objectives
Trial-specific objectives are to evaluate the feasibility ac-
cording to the following indicators:
Process
Recruitment rate
The recruitment rate will be defined as the number of
participants recruited per month. This information was
recorded in the study log at each site.
Retention rate
The retention rate will be calculated by dividing the
number of participants, who completed data collection
at T2 (post-intervention), T3 (3-month follow-up), T4
(6-month follow-up) and T5 (12-month follow-up) by
the number of participants who completed data collec-
tion at T1.
Ability to consent
The ability of patient participants to consent will be
measured by the number of participants who provided
informed consent and the number of consultee declarations
[16]. Additionally, incidence of cognitive and communication
impairments will be measured from the Screening and Post-
Screening and Assessor Case Report Forms.
Consent rate
The consent rate will be calculated by dividing the num-
ber of individuals who met inclusion criteria, by the
number who consented to participate in the trial.
Reasons why eligible individuals are not interested in
participating will be recorded by the PI/recruiting therap-
ist in the approach/screening log.
Eligibility criteria
The suitability and feasibility of eligibility criteria will be
determined by reviewing reasons for exclusion docu-
mented in the Approach/Screening Log and Screening
and Post-Screening Case Report Forms, and reviewing
characteristics of recruited patient participants docu-
mented in the Screening and Post-Screening Case Re-
port Forms
Willingness/ability of physiotherapists
The willingness or ability of physiotherapists to re-
cruit will be measured by subtracting the number of
patient participants screened and approached from
the number of admissions documented on the Approach/
Screening Log
Willingness of patients to be randomised
The willingness of patient participants to be randomised
will be measured by the recruitment rate, and number of
participants who refused as documented on the Approach/
Screening Log
Acceptability of the intervention
Acceptability of the intervention among patients, rela-
tives and physiotherapists will be measured by num-
ber of withdrawals (requested by patient, relative or
healthcare professional), all of the points about under
the heading “Process” in addition to qualitative data
collected via semi-structured interviews with patient
participants, their relatives and physiotherapists and a
focus group with physiotherapists.
Determining usual physiotherapy
Determining usual physiotherapy management for
people who have had a severe stroke receiving inpatient
early sub-acute stroke rehabilitation will be captured by
the Control Group Case Report Forms.
Sample size estimates
Sample size estimates, together with existing literature
and standard deviation of the outcome measures, will
help to inform power calculations for subsequent trials.
Resource
Burden
Patient participant and physiotherapist burden will be
measured by number of patient participants refusing
therapy sessions and follow-up assessments. This will
also be explored in semi-structured interviews with pa-
tients, their relatives and physiotherapists, focus group
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with physiotherapists, and field notes from blinded
assessor.
Cost effectiveness
Estimates of resource use and related costs for the
delivery of Standing Practice In Rehabilitation Early
after Stroke (SPIRES) will be measured through
semi-structured interviews exploring time required
for preparation for functional standing programme
session. Duration of functional standing frame
programme group session (total minutes) will be
captured in the Case Report Form and will be com-
pared with the duration (total minutes) of the usual
physiotherapy (control) group.
Management
Fidelity
Intervention fidelity, defined as adherent delivery of
the intervention, will be evaluated using a trial-
specific SPIRES checklist that outlined all components
of the functional standing frame programme interven-
tion, and usual physiotherapy control group to be
completed by an independent observer (e.g. physio-
therapist checked blood pressure, demonstrated, en-
sure foot sensors in situ and positioned safely,
position participant in frame etc.).
Participant adherence
The tolerance/adherence of the functional standing
frame programme to people who have had a severe
stroke will be measured by tracking (i) total number
of sessions completed; (ii) total number of minutes
standing; (iii) total number of sit to stand repetitions;
(iv) enjoyment; (v) effort; (vi) fatigue; and (vii) reasons
for non-completion of sessions, as documented by
treating physiotherapists in the Case Report Form.
Feasibility of outcome measures
The feasibility of the proposed outcome measures will
be measured by the number of primary and secondary out-
come measures completed and the ability to detect change
in this patient group with severe mobility impairment.
Orthostatic Hypotension protocol
The feasibility and acceptability of the Orthostatic
Hypotension protocol will be measured by the inci-
dence of orthostatic hypotension, the number of in-
complete sessions due to orthostatic hypotension and
the number of participants who received pharmaco-
logical or non-pharmacological (abdominal binders)
treatment.
Safety
Intervention
Safety of the intervention will be measured by the
number of adverse events and serious adverse events
that occur during the SPIRES intervention period (e.g.
falls, skin damage, infection, hospital admission,
death). The treating physiotherapists are responsible
for documenting any adverse events or serious ad-
verse events.
Data collection
Safety during data collection will be assessed by the
number of adverse events or serious adverse events that
occurred during the follow-up period. The blinded as-
sessors are responsible for recoding any adverse events
that occurred during data collection.
More specifically the objectives related to the qualita-
tive evaluation are to:
 Explore means by which the trial procedures
(timing and mode of participant recruitment,
information provision, methods of data collection
for example timing and content of outcome
measures) can be refined to maximise
recruitment, retention and acceptability in the
definitive trial
 Explore patient participants’ experience of the
functional standing frame programme
 Explore patient participants’ experience of being
randomised
 Explore patient participants’ reasons for, and
experience of, withdrawing from the trial
 Explore relatives’ influence in participants’ decision
to consent to participate, remain in the trial or
provide assent for their relative
 Explore physiotherapists’ attitudes, thoughts and
feelings of implementing the intervention and
whether they perceive a subsequent RCT to be
achievable
 Explore physiotherapists’ attitudes, thoughts and
feeling of the trial documentation and processes.
Trial design
This is a pragmatic, multi-centre, parallel single-blinded
two-armed feasibility RCT (Fig. 1).
Methods: participants, intervention and outcomes
Trial setting
Three healthcare sites (with four Stroke Rehabilitation Units)
will be involved in the trial, which is based in two counties in
the South West Peninsula of England. A full list of trial sites
is available via https://www.plymouth.ac.uk/research/spires.
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Eligibility criteria
Inclusion criteria for quantitative methods
The trial population will comprise individuals with a
confirmed clinical diagnosis of new (first or recurrent)
severe stroke, cerebral haemorrhage or infarct confirmed
by consultant or computed tomography (CT) scan and
leading to admission to the Stroke Rehabilitation Unit.
Participants will be:
1) Aged ≥ 18 years
2) Graded as mRS 4 or 5 and/or National Institutes
of Health Stroke Scale (NIHSS) ≥ 16 (severe or
Fig. 1 Trial flow chart. This figure represents the trial processes from assessing eligibility to data analysis
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very severe stroke and unable to stand without
support/mechanical aid and assistance of two
people)
3) Able to give informed consent or assent
received from a consultee (see recruitment
section)
4) Conscious and responsive to verbal
prompts.
Exclusion criteria for quantitative methods
Potential participants meeting any of the following cri-
teria will be excluded from trial participation:
1) Systolic blood pressure ≤ 100 mmHg or ≥
220 mmHg at rest, lying or sitting
2) Oxygen saturation ≤ 87% with or without
supplementary oxygen (e.g. severe acute/chronic
cardiorespiratory disease)
3) Resting heart rate of ≤ 40 or ≥ 110 beats per minute
(e.g. cardiovascular instability)
4) Temperature ≥ 38.5 degrees centigrade or ≤ 35
degrees centigrade
5) Orthopaedic impairments which prevent full weight
bearing in standing
6) Malnutrition Universal Screening Tool score of
≥ 2, or deemed to be not meeting nutritional
demands for therapeutic interventions by
dietician
7) Documented clinical decision for receiving end of
life care
8) Unstable coronary or other medical condition
that is judged by the Principal/Chief Investigator
(PI/CI) or clinical team to impose a medical
risk to the patient by involvement in the trial
9) Assessed functionally by specialist clinicians as being
a risk to themselves or others due to their inability
to follow non-verbal prompts or are behaving
erratically
10) Immobile and not weight bearing pre-stroke
11) Additional neurological deficits unrelated to the
current or past stroke (e.g. peripheral
neuropathy or multiple sclerosis), because
these impairments are not related to the
condition of interest)
12) Weight of 115 kg or more, this is the weight limit
on the standing frames
13) Being discharged out of county, e.g. admitted
during holiday/visit to Cornwall or Devon because
they would be unable to participate in follow-up
assessments
14) If people are registered in another trial, the CI will
be contacted to ensure there is no conflict between
trials
15) Non-English speaking
Inclusion criteria for qualitative methods
Patient participants
1) Are able to use a range of communication methods
including speech, gesture and/or writing as
determined by the ConsentSupport Tool as well as
other assessments determined appropriate by SLT
based on the SRU, e.g. able to answer the questions
in the patient-report outcome measures at the
3-week follow-up assessment visit
2) Able to recall involvement in the study or study
processes with or without prompts or aids (e.g.
study documentation) as required.
Relative participants
1) Aged ≥ 18 years
2) A family member/close friend of a participant
registered in the SPIRES feasibility trial
3) Able to provide written informed consent
Physiotherapist participants
1) Registered physiotherapist working on the Stroke
Rehabilitation Unit for 3 or more days in each
week
2) Able to provide written informed consent
Intervention
The intervention will be delivered in the Stroke
Rehabilitation Unit over a period of 3 weeks and will
start as early as possible after randomisation to
ensure that the treatment can be completed during
the participant’s inpatient admission. The functional
standing frame programme involves a maximum of
30 min using the standing frame (standing and
repeated sit to stand) plus an additional 15 min to
provide time for usual care physiotherapy, where par-
ticipants may practise transfers, upper limb activities
or activities chosen by participants or guided by phys-
iotherapists. Participants will be asked to undertake
the functional standing frame programme once a day,
for a target of a minimum of 5 days per week which
is aligned with the RCP Guidelines [34].
The initial frequency and duration of standing may
vary according to physical capability as assessed by
the treating physiotherapist. The aim is to progress
standing time by 30% in each session, up to the
maximum of 30 min. Each treating therapist will use
their individual clinical reasoning when evaluating
participants’ tolerance to standing and ability to tol-
erate incremental increases in standing duration. The
associated Work Instruction (Additional file 1) con-
tains specific details of how to implement this.
Standing duration for each session will be recorded
by the treating physiotherapist.
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Participants will move from sitting to standing with
aid of an electronic power lifter and a physiothera-
pist(s) and assistant as required. Foot sensors (integral
to the frame design or customised) will record load
through each leg when standing in the frame. The
aim is for the foot sensors to be used as biofeedback
to encourage equal weight distribution during quiet
standing and sit-to-stand. Whilst standing, partici-
pants will be supported in the frame with straps at
the ankle, knees, hips and trunk (if required). They
will be encouraged to undertake progressive task-
specific activities:
 Repeated sit-to-stand (aiming for 8–12 repetitions to
facilitate strengthening)
 Table top games encouraging postural adjustments
and use of upper limbs
 Reductions in postural support, e.g. reducing hip
and trunk strap tension during standing,
elimination of electronic power lifter for sit-to-
stand
Should participants improve to the extent where
support from the standing frame is not required;
then, unsupported standing/walking can be pro-
gressed outside of the frame to optimise physical
recovery for the remainder of the 3-week interven-
tion if indicated. Repeated sit to stand (8–12 repeti-
tions) should, however, be continued throughout the
30 min session.
Physiotherapists will record activities undertaken
during every session using a Physiotherapy Content
Recording Tool (Additional file 2). This checklist is
based on the Stroke Physical Therapy Intervention
Tool [66] which provides a system for recording
physiotherapy treatment for stroke patients and has
been modified to reflect current clinical practice in a
sub-acute rehabilitation setting. Recording physiother-
apy interventions during sub-acute stroke rehabilita-
tion will enable usual physiotherapy management to
be defined and inform the subsequent main trial. This
will include number of repetitions of sit-to-stand, ac-
tivities undertaken whilst standing, reductions in pos-
tural support, duration of stand and activities
undertaken in the 15 min of usual physiotherapy.
For the first three sessions (or longer if deemed appro-
priate by physiotherapists), blood pressure will be
assessed both prior to and during the functional stand-
ing frame programme. This is based on the protocol
used in the feasibility and safety testing of a very early
rehabilitation trial [5]. If, when standing, a participant
demonstrates OH (decrease in systolic blood pressure of
≥ 20 mmHg, or a reduction in diastolic blood pressure
of ≥ 10 mmHg upon changing body position from a
supine position to an upright posture, or sitting to
standing) standing will be modified or, if required,
ceased for that session. Details are contained in a trial-
specific work instruction document.
If the participant demonstrates OH, a protocol to
treat OH using non-pharmacological interventions
will be implemented, in collaboration with the par-
ticipant’s ward-based doctor. This protocol will pro-
vide details about application and monitoring of a
compression garment and continued monitoring of
blood pressure (available from corresponding author
on request).
To standardise and optimise implementation of the
functional standing frame intervention, all treating
physiotherapists will be provided with face-to-face
trial specific training by the CI and be included on
the delegation log, authorised by the CI or PI. They
will be provided with a link to the trial website,
which will include videos demonstrating standing, ex-
amples of how to progress the programme using case
scenarios, downloadable schema of suggested task-
specific exercises/activities, advice on safety issues and
“frequently asked questions”. It will also include trial
details (e.g. background, rationale) and CI’s contact
details. This will complement a trial-specific work
instruction.
Control (usual physiotherapy)
This is defined as routine physiotherapy stroke rehabili-
tation for 45 min per day (or as long as tolerated) for a
target of a minimum of 5 days per week, which is
aligned with RCP Guidelines [34]. There is no agreed
upon definition of what constitutes usual physiotherapy;
thus, there is likely to be variation in usual physiother-
apy due to physiotherapists’ preferences, experience and
training. Physiotherapists will record activities under-
taken during every session using the Physiotherapy
Content Recording Tool (Additional file 2) to enable
description of usual physiotherapy across all four Stroke
Rehabilitation Units. It will also capture any instances of
protocol deviation where physiotherapists implement a
standing frame programme with participants in the
control group. The protocol, and face-to-face training
sessions, advise physiotherapists not to change their
usual physiotherapy practice.
It is expected, although not required, that the same
physiotherapists will be delivering both interventions
(e.g. implementing both the functional standing frame
programme and usual physiotherapy). Clear instruc-
tions about content of the intervention and control
group, combined with fidelity checking, aim to avoid
any conflict. However, potential for bias is acknowl-
edged, and therefore, a stepped wedge cluster RCT
[28] may be considered for the future main trial. This
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would allow every site (cluster) to deliver both the
control and the intervention, with every cluster
switching from control to the intervention, but at dif-
ferent time points.
Standardisation of the intervention
Treating physiotherapists from each of the three
healthcare sites will perform the interventions as part
of their clinical role; the CI and a blinded assessor
(employed specifically for one site) will undertake the
assessments.
Use of standing frames is incorporated within
undergraduate physiotherapy training and is a
recognised core skill for neurological physiothera-
pists. To standardise and optimise implementation of
the intervention, treating physiotherapists will re-
ceive face-to-face training and an information pack.
This includes a written template of what is required
to be undertaken within each session (Figs. 2 and 3) and
a link to the trial website.
Treating physiotherapists and the assessors are re-
quired to record any deviations from the protocol on a
Protocol Deviation form.
Inter-rater reliability will be assessed for the blinded asses-
sors on all outcome measures (both primary and secondary).
1) Proposed primary outcome measures
Fig. 2 Flow chart 1. Procedure for implementing the functional standing frame programme whilst monitoring BP. This figure represents the
procedures for the functional standing frame programme intervention. This first flowchart encompasses the monitoring of blood pressure to
ensure participant is safe to continue with the intervention
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The proposed primary outcome measure assesses
functional ability in performing activities of daily living.
Functional ability was identified as being important and
a priority for people with severe stroke and their rela-
tives during discussions in the development of this feasi-
bility trial.
The Barthel Index of Activities of Daily Living (BI)
[41] is frequently used in stroke clinical trials, al-
though was not designed specifically for clinical trials
or the stroke population. The BI rates a person’s de-
gree of independence performing functional self-care
(feeding, grooming, bathing, etc.) and mobility activ-
ities (transferring in/out of bed/chair, walking, etc.). A
major limitation of the BI is its floor effect [51], and
as a result, it has limited ability to detect change at
extremes of ability, making it less discriminating in
severe stroke [55].
This feasibility trial provides the opportunity to inves-
tigate whether an alternative functional outcome meas-
ure is more sensitive to change in people with severe
stroke. Therefore, the Edmans Activities of Daily Living
Index for Stroke Patients [20] will also be used. This
measure has cover all the categories included in the BI;
however, the response categories are independent, super-
vision, help of one and help of two, as opposed to the BI
responses which are only dependent or independent for
each item assessed.
2) Proposed secondary outcome measures
Blood pressure in lying and sitting to determine pres-
ence of orthostatic hypotension using sphygmoman-
ometer: Orthostatic hypotension is a decrease in
systolic blood pressure of ≥ 20 mmHg, or a reduction
Fig. 3 Flowchart 2. Procedure for implementing functional standing frame programme when OH stabilised. This second flowchart provides a
diagramatical representation of procedures to follow for the functaional standing frame programme for patient participants who have been
deemed to have stable blood pressure
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in diastolic blood pressure of ≥ 10 mmHg upon
changing body position from a supine position to an
upright posture, or sitting to standing [39]. This feasi-
bility trial will record the incidence of OH and
whether OH limits participation in the functional
standing frame intervention.
Control of trunk using Trunk Control Test [18]: The
Trunk Control Test has demonstrated construct and
predictive validity [22] and concurrent validity and inter-
rater reliability [12].
Knee extension muscle strength (left and right) using
hand held dynamometer [33, 52]: Knee extensor strength
is strongly correlated to common daily functional
activities such as the ability to sit to stand, stand and
walk in people with sub-acute stroke [33]. It is reliable
in measuring lower limb strength in people with stroke
(ICC = 0.88–0.98) [52].
Length of hip flexors, hamstrings and ankle plantar-
flexors (left and right) using manual universal goniom-
eter [7]: Passive range of movement of these muscles
will be measured on both lower limbs. Intra-rater reli-
ability using goniometry to measure ankle plantarflexor
length was moderate to good (ICC 0.719–0.892) and
inter-rater reliability was moderate (ICC 0.725–0.741) in
people with stroke.
Muscle tone in hip adductors, hamstrings and ankle
(left and right) using Modified Ashworth Scale [24]:
The Modified Ashworth Scale shows good inter-rater
reliability hip and knee (weighted kappa = 0.82) and
ankle (weighted kappa = 0.74); moderate intra-rater
hip (weighted kappa = 0.45); good intra-rater reliabil-
ity for knee (weighted kappa = 0.62) and very good
for the ankle plantarflexors (weighted kappa = 0.85)
people with stroke [25].
Mood using Patient Health Questionnaire (PHQ-9)
[72] or Stroke Aphasia Depression Questionnaire-10
(SADQ-10) for participants who have aphasia [61]:
PHQ-9 shows good sensitivity (78%) and specificity
(96%) for any depression diagnosis regardless of age,
gender or ethnicity [72] and the SADQ-10 shows good
internal consistency (Cronbach’s alpha = 0.80 and a split-
half reliability of r = 0.81) [61].
Health-related quality of life using Stroke and
Aphasia Quality of Life Scale-39 [30] and the
EuroQol Group 5 Dimensions, 5 Levels (EQ-5D 5L)
[29]: The Stroke and Aphasia Quality of Life Scale-39
has high internal reliability (alpha = 0.74–0.94) and
test re-test reliability is also good (ICC = 0.89) [30].
However, it is unknown whether it is feasible for
people with severe stroke to use this outcome meas-
ure due to communication and cognitive impairments.
The EQ-5D-5L shows moderate responsiveness to
change (SRM = 0.63) and a minimally clinically
important difference of 0.10 [11].
Fatigue using aVisual Analogue Scale (Additional file 3)
to enable people with aphasia to also rate their level of
fatigue [36].
Qualitative evaluation
Qualitative methodology will enable exploration of the
thoughts, feelings and experiences of trial participants,
their relatives and treating physiotherapists/PIs. Strati-
fied purposive sampling will be used to achieve max-
imum variation to request semi-structured interviews
with 16 participants (approximately six in the func-
tional standing frame group, six in the usual physio-
therapy group and four people who decline to
participate or withdraw), eight relatives and eight
treating physiotherapists. A combination of face-to-
face, telephone or Skype will be offered for the inter-
views to inform the most appropriate method for the
definitive main trial. The aim of the qualitative inter-
views is to address several uncertainties or unknowns
including recruitment, retention, practical implemen-
tation of the intervention, acceptability/tolerance of
the intervention, informed consent, and suitability and
acceptability of outcomes measures to inform the de-
sign and implementation of the definitive main trial.
People with mild to moderate aphasia will be inter-
viewed as it is important to seek the perspectives and
experiences of people with aphasia due to its high
prevalence in people with stroke. However, people
with severe aphasia (unable to complete the patient-
report outcome measures) will be unable to partici-
pate due to inability to comprehend and/or express
their views and will therefore be excluded.
All physiotherapists involved in delivering the trial
(PIs and treating physiotherapists) will be invited to a
focus group at the end of the recruitment period to
discuss their experiences of delivering the trial (par-
ticipant recruitment, documentation, delivery of the
intervention, etc.) to further evaluate and improve
procedures for the definite trial. All interviews and
focus group will be digitally recorded and transcribed
verbatim.
Sample size
As a feasibility trial, a formal sample size calculation
based on considerations of power is not appropriate;
this trial is not statistically powered to detect
between-group clinically meaningful differences in a
primary outcome. One of the objectives of this trial is
to provide robust estimates of the likely rates of re-
cruitment and follow-up, as well as provide estimates
of the variability of the proposed primary and second-
ary outcomes to inform sample size calculations for
the planned definitive trial. There is no consensus on
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the recommended number of participants required for
a feasibility trial, with published “rules of thumb” ran-
ging from 20 to 70 or more participants, when the
planned primary outcome is of a continuous nature.
A recent paper recommended a feasibility trial sample
size should recruit 25 participants per allocated
group, if the planned definitive trial will have a two-
arm parallel group design, with 90% power and two-
sided 5% significance level, to detect a “small” stan-
dardised effect size [71]. Therefore, this feasibility trial
aims to recruit 50 participants in total.
A target sample size of 50 patient participants will
allow the follow-up rate to be estimated to within ±
15%. The follow-up rate at 12 months is estimated to
be 70%, which would provide follow-up outcome data
on a minimum of 35 participants across both allo-
cated groups and three sites.
Recruitment
Identification and recruitment will be by a healthcare
professional on admission to one of four inpatient
Stroke Rehabilitation Unit participating in the trial.
This will be supported by the local NIHR Clinical
Research Network. The healthcare professionals will
log all admissions and screen patients for their
stroke severity. All patients classified as a severe
stroke will be screened for their eligibility, and any
eligible participants will be approached within 48 h
of the participant being deemed medically fit for re-
habilitation or as soon as practicable.
Methods: assignment of interventions
Randomisation and concealment
The randomisation process will follow a strict and
auditable protocol. Randomisation will take place
after all baseline assessments have been carried out;
the blinded assessor will input relevant participant
details into the trial website, and randomisation will
subsequently be conducted by the Peninsula Clinical
Trials Unit (PenCTU) data programmer via the se-
cure web-based system. The allocations will be
computer-generated by the PenCTU in conjunction
with an independent statistician, in accordance with
the PenCTU’s standard operating procedure. The
randomisation list and the program that generated it
will be stored in a secure network location within
the PenCTU, accessible only to those responsible for
provision of the randomisation system. This will en-
sure concealment of both the clinical staff undertak-
ing recruitment and the blinded assessor to each
participant’s allocated group.
A minimisation procedure (which has a random
element) during the randomisation process will be
used to reduce possible imbalance between the two
groups (intervention and control). Minimisation
factors are:
1. Fatigue scored by the participant (if they are able) at
baseline assessment, as measured using a Visual
Analogue Scale (VAS) (fatigue (VAS: 4–10) vs. no/
minimal fatigue (VAS: 0–3)) (Additional file 3)
2. Presence of OH at baseline, tested using manual
sphygmomanometer and a standardised protocol
After randomisation, an automatic email will be
sent by PenCTU to the relevant treating physiother-
apist to notify them of each participant’s allocated
group. Notification that randomisation has taken
place (but no details regarding individual participant’s
allocated group) will also be sent to the CI. Access to
the randomisation code and allocation list will be
confined to the CTU data programmer; no one else
in the trial team will be aware of participant’s allo-
cated group until formal randomisation is completed,
hence maintaining effective concealment.
Blinding
Trial participants and treating physiotherapists are
unable to be blinded due to the nature and complex-
ity of the intervention. However, the assessors
undertaking the outcome assessments will be blinded
to all participant’s allocated group until after the 3-
week assessments have been completed. To under-
take the qualitative evaluation, one assessor will be
unblinded to group allocation for up to 16 partici-
pants. A member of the research team who does not
require to be blinded will undertake the stratified
purposive maximum-variation sampling.
The initial baseline assessment will be undertaken once
consent/assent has been received and prior to randomisa-
tion. Every effort will be made throughout the trial to en-
sure assessments are blinded for the remaining 34
participants whose allocated group will not be unblinded.
Treating physiotherapists and/or participants will be
reminded not to discuss their allocated group with the as-
sessor during any interaction. At each assessment time
point, the blinded assessors will be asked to record if they
were unblinded to group allocation, and if so, the reasons
for this as well as recording which group they think the
participant was allocated to.
Methods: data collection, management, and
analysis
Data will be collected using a range of methods: semi-
structured interviews with patient participants, their relatives,
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and treating physiotherapists/PIs, Case Report Forms and
observer completed fidelity checklists.
A) Feasibility outcomes
Feasibility indicator Outcome measures Data collection
method
Process
Recruitment
rate
% of participants
recruited/time
Case Report Forms
Retention
rate
% of participants
completed T1, T2,
T3, T4, T5
Case Report Forms &
Withdrawal Forms
Ability to
consent
% of participants
consenting
Screening/Approach
Logs
Consent rate % of consultee
declarations
Case Report Forms
Eligibility
criteria
% of admissions
screened & eligible
Screening/Approach
Log, Recruitment
rate, Interview &
Focus Group
Willingness of
physiotherapists
to recruit
% of admissions
screened &
approached
Recruitment rate,
Interview & Focus
Group
Willingness of
patients to be
randomised
% of participants who
refuse to enrol in the
trial
Recruitment Rate,
Interviews & Focus
Group
Acceptability of the
intervention
% of withdrawals Case Report Forms &
Interview
Determining usual
physiotherapy
Frequency specific
physiotherapy
interventions are
implemented
Case Report Forms
Resources
Burden % of participants
refusing physiotherapy
sessions and follow-up
assessments
Case Report Forms &
Interviews & focus
group
Cost effectiveness n = duration (minutes)
of functional standing
frame programme
session
Case Report Forms &
Interviews
Management
Fidelity Observe intervention
and control group
sessions
Fidelity Checklists
Participant
adherence
n = sessions per week Case Report Forms
n =minutes in
standing
Case Report Forms &
interview
n = sit to stand
repetitions
Case Report Forms &
interview
n = Yes; n = No for
enjoyment
Case Report Forms &
interview
Score out of 10 for
effort
Case Report Forms &
interview
(Continued)
Score out of 10 for
fatigue
Case Report Forms &
interview
Orthostatic
hypotension
protocol
% incidence of
orthostatic
hypotension
Case Report Forms
% of incomplete
sessions due to
orthostatic
hypotension (OH)
Case Report Forms
Safety
Intervention n = AE & SAE Adverse Event and
Serious
Data collection n = AE & SAE Adverse Event Forms
T1: baseline; T2: post-intervention period; T3: 3 months;
T4: 6 months; T5: 12 months
B) Clinical outcome measures
Standardised, validated clinician-rated and patient self-
reported clinical outcomes will be measured in both
groups at baseline, post-intervention (within 1 week) and
follow-up (3, 6 and 12 months ± 1 week). Assessments at
these time points will be conducted wherever the partici-
pant is residing. Due to the average length of stay in in-
patient stroke rehabilitation, follow-up assessments at 3, 6
and 12 months are likely to be in the participants’ own
home or residential/nursing care facility. All the outcome
measures listed below will be undertaken at each of the
follow-up trial visits.
Economic evaluation
As this is a feasibility trial, an economic evaluation will
not be carried out. However, the data set for the EQ-5D
5L will be collected to determine if it is feasible to col-
lect these data from people with severe stroke.
Process evaluation
Process evaluation is a key part of the intervention
development process to enable conclusions to be made
about the strengths and weaknesses of a trial. This will
facilitate decision-making for the definitive main trial.
The Medical Research Council guidance [43] recom-
mends process evaluation and highlights the importance
of capturing fidelity (whether the intervention was deliv-
ered as intended); dose (the quantity of intervention im-
plemented) and reach (whether the intended target
population comes into contact with the intervention,
and how).
Fidelity will be measured using several mechanisms: (i)
treating physiotherapists will record the content of their
physiotherapy sessions and adverse events in the Case
Report Forms; (ii) an independent assessor will observe
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one intervention and one control group session at each
of the four Stroke Rehabilitation Units at random
timepoints during recruitment and complete a fidelity
checklist (Additional file 4); (iii) during qualitative
interviews with treating physiotherapists.
Data analysis
A detailed statistical analysis plan will be developed by
the lead author and approved by statisticians and the
Trial Steering Committee, prior to the final database
lock and analyses. The primary descriptive analyses will
be on an intention to treat basis. The analyses of the
quantitative data will be in two stages, in line with
CONSORT guidelines for pilot and feasibility trials [21].
Stage 1 will summarise the feasibility outcome data.
Stage 2 will summarise the clinical outcome data at
each time point. Descriptive statistics of the clinical
outcome data will be produced for each trial arm. No
formal hypothesis testing will be undertaken of the
data.
Qualitative analysis
The qualitative data will be transcribed verbatim and
analysed using thematic analysis [9], using a framework
matrix as a data management tool [58, 59].
The qualitative data will be transcripts from one-to-
one semi-structured interviews with patients, their rela-
tives and physiotherapists, and the physiotherapist focus
group. Anonymised transcribed data will be entered into
NVivo software [50]. Narratives generated from the in-
terviews will provide information about the uncertainties
and unknowns of this feasibility trial. Interview and
focus group participants (patients, relatives and physio-
therapists) will be invited to review an initial draft to en-
sure the analysis represents an accurate overview of
participants’ views, experiences and recommendations.
Safety monitoring
Throughout the trial, all possible precautions will be
taken to ensure participant safety and wellbeing. Patient
participants will be monitored for adverse events via
completion of an aphasia friendly brief interview after
every therapy session during the 3-week intervention
period. Treating physiotherapists will be asked to report
adverse events related to the interventions (e.g. falls,
musculoskeletal aches and pains, fatigue) and all serious
adverse events (e.g. prolonged/required hospitalisation,
life threatening event, death, significant medical event,
persistent/significant disability/incapacity) to the re-
search team, regardless as to whether they are thought
to be related to the intervention or not and whether they
believe these serious adverse events are related to the
intervention or not. Additionally, participants will be
monitored during their scheduled follow-up visits for ad-
verse events and serious adverse events. Adverse events
will be reviewed regularly by the Trial Management
Group to determine the relatedness of these events to
the intervention. Serious adverse events will be reviewed
by the Trial Steering Committee.
Retention rates and withdrawal
Each participant has the right to withdraw voluntarily from
the trial at any time, without any effect on their current or
future care. This may be through personal choice (i.e. they
withdraw their consent), where it becomes impossible to
provide outcome data or comply with any other trial
procedures for whatever reason, following consultation/
recommendation of a health professional following an
adverse event or serious adverse event, or a significant
protocol deviation, such as a participant being found to be
ineligible post-randomisation. Participants found to be in-
eligible will be withdrawn. Reasons for withdrawals will be
recorded and reported by the treating physiotherapist using
a standardised proforma. Participants who wish to stop par-
ticipating in the functional standing frame group will be
asked to remain in the trial for follow-up assessments as
per protocol if this is possible, although it is acknowledged
that if a participant is receiving end of life care this would
not be appropriate.
Determining progression to the full trial
Progression to a full trial application will occur if
minimum success criteria are achieved in key feasibility
aims and objectives, and/or if solutions can be identified
to overcome any issues. These criteria will be finalised in
discussion with the Trial Steering Committee, but are
likely to include a minimum of:
 70% recruitment of the intended 50 patient
participants within the 13-month recruitment
window
 80% of consented patient participants randomised to
the intervention group engaging with and adhering
to a minimum of five session per week during the
three-week SPIRES intervention
 80% completion rate of outcome measures
(including follow-up)
Trial oversight
There are two committees involved in the set-up, manage-
ment and oversight of this trial: the Trial Management
Group (TMG) and Trial Steering Committee (TSC).
The TMG comprises those individuals involved in the
development of the protocol and the day-to-day running
of the trial. The responsibility of this group is to ensure
all practical details of the trial are progressing and that
everyone within the trial understands them. This
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includes monitoring adverse events, recruitment and at-
trition rates, the project timeline and finances. It will
also include responsibility for the release of the trial re-
sults and publications. The TMG will meet approxi-
mately monthly.
The TSC is responsible for overseeing the conduct of
the trial on behalf of the Sponsor and funder, and
comprises a group of experienced trialists with majority
independent representation including patient and
members of the public. The TSC will monitor the
scientific integrity of the trial including trial progress,
adherence to the protocol and the consideration of new
information. The TSC will also be responsible for
reviewing accumulating safety data to monitor
participant safety. TSC members will be constructively
critical of the ongoing trial, but also supportive of its
aims and methods.
Data management, audit and monitoring
The PenCTU will be responsible for data management
for the trial. Data will be recorded in trial-specific Case
Report Forms by the treating physiotherapists and
assessors. Completed forms will be passed to the
PenCTU and entered onto a secure web-based data-
base. All data will be double entered and compared
for discrepancies. Discrepant data will be verified
using the original paper data sheets. Data will be
collected and stored in accordance with the Data
Protection Act 1998 and will be accessible for the
purposes of monitoring or auditing.
Ethics
The trial will be conducted in accordance with the ethical
principles that have their origin in the Declaration of
Helsinki, 1996, the principles of Good Clinical Practice,
and the Department of Health Research Governance
Framework for Health and Social Care, 2005.
All participants (patients, relatives and physiotherapists)
will be provided with a Participant Information Sheet
approved by HRA and provide written informed consent. A
consultee will declare assent if the patient participant lacks
capacity to provide informed consent. Physiotherapists will
obtain informed consent or assent from participants. The
CI will obtain consent for interviews with relatives and
physiotherapists.
Confidentiality
Participants’ anonymity will be maintained on all documents.
Data will be collected and stored in accordance with the
Data Protection Act 1998 and will be accessible for the
purposes of monitoring or auditing. Unique study numbers
will be used on all documentation.
Dissemination
The results of this feasibility trial will inform the design
of the anticipated definitive trial, rather than directly
inform clinical decision making, since clinical and cost
effectiveness cannot be determined at this level. Hence,
dissemination, regardless of outcome of this feasibility
trial, will focus on publication of the feasibility
outcomes, and related methodological issues, in open
access peer reviewed journals.
On completion, the full trial report will be accessible on
the trial website (https://www.plymouth.ac.uk/research/
spires) and via the funding body website, as will the full
protocol. This protocol (Version 1.1, dated 28/02/2017)
has been written in line with Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
Guidelines [10]. The Consolidated Standards of Reporting
Trials (CONSORT) (Additional file 5) for pilot and
feasibility trials [21] and the Template for Intervention
Description and Replication (TiDIER) Guidelines [32]
(Additional file 6) will be reviewed prior to submitting
future publications of the trial results. Authorship of
articles will be by the trial team; professional writers will
not be used.
Results of this feasibility trial will be presented at
national and international conferences, for example UK
Stroke Forum, to induce enthusiasm for the potential
future trial. Summaries will be posted on to the websites/
newsletters of the organisations involved in the
recruitment process including Stroke Association and
social media platforms such as Twitter to optimise
dissemination. In addition, all participants (patients,
relatives and physiotherapists) will be offered a lay
summary of results and a clinically oriented summary will
be provided to recruiting centres. A key output will be an
application for funding for a definitive trial, if the results
of the feasibility trial meet the criteria for progression.
Discussion
The importance of early mobilisation for people with
severe stroke has been highlighted by people with severe
stroke, their relatives and clinicians working in Stroke
Rehabilitation Units. This was highlighted during early
discussions with patients, their relatives and clinicians
where the research topic was strongly endorsed as
meaningful and relevant and aligned with patients’ key
priorities to “get up and move straight away” after their
stroke. This led to the development of the research
question and has continued to inform and influence the
trial design and remained integral to the development of
the methodology, grant application, trial protocol and trial
monitoring. The functional standing frame programme
has been developed with the aim of addressing this
important issue; however, a full evaluation of its
effectiveness is essential to inform evidence-based clinical
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decision-making. Best practice guidance emphasises the
need to thoroughly test the feasibility and acceptability of
both interventions and trial evaluation procedures prior to
undertaking a full-scale assessment of effectiveness [14].
The functional standing frame intervention specifically
aims to address the key priorities of patients, their relatives
and clinicians, optimising general function, standing and
walking. Whilst discussions with people who have had a
severe stroke and their relatives identified the importance
of people with severe stroke being actively involved in
research, they identified several barriers (e.g. fatigue,
exercise tolerance, communication difficulties, being
physically and psychological overwhelmed and memory
difficulties), which are identified and acknowledged in the
literature as barriers to recruitment and retention in stroke
clinical trials [8]. These barriers have been carefully
considered by utilising relevant literature [4] and resources
such as Clinical Research Networks and people who have
suffered stroke, their relatives and stroke specialist
therapists to facilitate inclusion of people with severe
stroke. Additionally, the qualitative component will provide
the opportunity to explore the impact of the functional
standing frame programme intervention, being randomised
into the usual physiotherapy group, recruitment and
retention.
The usual physiotherapy group provides the opportunity
to describe what interventions physiotherapists are
currently using to facilitate optimal function after severe
stroke, using the Physiotherapy Content Recording Tool.
Key clinical guidelines recommend interdisciplinary
rehabilitation, of which physiotherapy is primarily aimed at
optimising and maintaining activities of daily living, usually
starting within the first few days’ post-stroke [34]. There is
strong evidence favouring task-specific and high repetitive
task-oriented training; however, randomised controlled
trials are needed to address which patients may benefit
from a specific intervention and at what time post-stroke
interventions should be initiated [68]. This underpins the
rationale for this feasibility randomised controlled trial to
investigate the effects of a functional standing frame
programme versus usual physiotherapy in people with
severe sub-acute stroke on function, quality of life and
neuromuscular impairment.
Trial status
Recruitment opened in December 2016.
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